Therma Bright's AcuVid™ COVID-19 Rapid Antigen Saliva Test This week will have the final results of the AcuVid™ Saliva / RT-PCR Test FDA Clinical Study. Previous tests confirm the performance quality and ease-of-use of the AcuVid™. AcuVid™ achieved comparable, and in some cases, better performance results than other leading COVID-19 rapid antigen tests available on today's market.
Therma Bright's AcuVid™ COVID-19 Rapid Antigen Saliva Test offers quick results, convenience, comfort and cost affordability; all of which are all key features that customers and global communities want to help stop the spread of this mutating Covid-19 virus. Moreover, the AcuVid™ saliva test has successfully been tested against many of the key variants, including the Delta B.1.617.2, P.1, P.2 and B.1.1.7 variant.
"Our nation, along with so many others, have been battling an unseen enemy for over a year with this ongoing global COVID-19 pandemic'" shared former Pennsylvania Governor Tom Ridge, first Secretary for the US Department of Homeland Security. "Therma Bright's clinical study including its easy-to-use, 15-minute and smart-enabled COVID-19 antigen saliva test makes it an ideal solution to help our communities deal with the effects of this virus and help to mitigate its spread and variant mutations."